Corbus Pharmaceuticals Holdings, Inc. (LON:0SZI)
London
· Delayed Price · Currency is GBP · Price in USD 8.10
-0.10 (-1.19%)
At close: Feb 21, 2025
LON:0SZI Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
78.81M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Genus | 668.80M |
Corbus Pharmaceuticals Holdings News
- 26 days ago - Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 6 weeks ago - Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies - Seeking Alpha
- 4 months ago - Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 4 months ago - Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - GlobeNewsWire
- 5 months ago - Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit - GlobeNewsWire